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Introduction: Semaphorin 4A (Sema4A) plays critical roles in many physiological and pathological processes
including neuronal development, angiogenesis, immune response regulation, autoimmunity, and infectious
diseases. The present study aimed to investigate its expression and biological activity in rheumatoid arthritis (RA).
Methods: RNA and protein were isolated from synovial tissues in RA and osteoarthritis (OA) patients. Treatment with
recombinant human Sema4A (rhSema4A) or small interfering RNA (siRNA) was applied to examine its effect on the
biological activity of synovial fibroblasts of RA (RASFs). Expression of Sema4A and NF-κB were measured by quantitative
RT-PCR (qRT-PCR) and Western blot after lipopolysaccharide (LPS) stimulation. Chromatin immunoprecipitation (ChIP)
and siRNA targeting p50 and p60 were applied to detect the regulation of Nuclear factor kappa (NF-κB) on Sema4A.
Sema4A, interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α) secretion were measured by
ELISA-based assays.
Results: Increased levels of Sema4A were detected in the synovial tissue and fluid of patients with RA compared
with those with OA. Furthermore, synovial fluid level of Sema4A correlated with Disease Activity Score (DAS) in RA.
Treatment with rhSema4A promoted invasion of RASFs by upregulating the expression of Matrix metallopeptidase3
(MMP3), MMP9, alpha-smooth muscle actin(α-SMA), and Vimentin, and exacerbated inflammation by promoting the
production of IL-6 in RASFs, as well as IL-1β and TNF-α in THP-1 cells. The induction of IL-6 and TNF-α by Sema4A was
confirmed at the protein level in fluid samples from patients with RA. Knock-down experiments showed the participation
of Plexin B1 towards rhSema4A in the induction of cytokines. In addition, LPS stimulation induced Sema4A expression
in RASFs in an NF-κB-dependent manner, and rhSema4A treatment could also activate NF-κB signaling.
Conclusions: These findings suggest an NF-κB-dependent modulation of Sema4A in the immune response. Further,
increased expression of Sema4A is required to promote inflammation of RA.Introduction
RA is characterized by chronic inflammation leading to
progressive destruction of cartilage and bone [1]. Among
the cells located in the inflamed joint, synovial fibro-
blasts are important players driving inflammation and
bone erosion [1]. They are recognized as a source of cy-
tokines such as IL-6 or receptor activator for nuclear
factor-κ B ligand (RANKL), which activate immune re-
sponse and osteoclastogenesis [2]. The study of mole-
cules and mechanisms that regulate their biological
activity could provide insight into the pathogenesis of* Correspondence: chang_qf@sina.com
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ment of new therapeutic strategies.
Semaphorins are a family of cell surface and soluble pro-
teins originally identified as axon guidance factors that
control the development of the central nervous system
[3]. They are grouped into eight classes based on their
structural domains, with classes 3–7 contributing the ver-
tebrate semaphorins [4]. A previous study reported that
decreased expression of semaphorin 3A is correlated with
disease activity and histological features of RA [5].
Another family member, semaphoring 5A (Sema5A), con-
tributes to the pathogenesis of RA through antigen-
independent T cell and natural killer (NK) cell activation
[6]. Further, patients with RA exhibit significantly elevated
density of Sema3C-positive cells in synovial tissue when
compared with patients with osteoarthritis (OA) or peoplee is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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relationship between semaphorins and RA.
In the immune system, Sema4A is preferentially
expressed on dendritic cells (DC) and B cells [8, 9]. It
has three known receptors: Tim-2, Plexin B1, and Plexin
D1 [10, 11]. Sema4A activates a specialized and re-
stricted genetic program in macrophages able to sustain
angiogenesis and participates in their recruitment and
activation in inflammatory injuries [12]. Recently, a
Sema4A-neuropilin-1 (Sema4A-NRP1) axis was reported
to maintain T regulatory (Treg) cell stability, highlight-
ing this pathway as a potential therapeutic target that
could limit Treg-cell-mediated tumor-induced tolerance
without inducing autoimmunity [13]. However, to date,
the exact expression amounts and function of Sema4A
in RA, especially synovial fibroblasts of rheumatoid arth-
ritis (RASFs), remain to be determined. Thus, in this
study, we focus on the expression and biological activity
of Sema4A in RA, which highlights its role in the patho-
genesis of RA.
Materials and methods
Sample collection and cell culture
Synovial tissue and fluid samples were collected during
knee joint replacement surgery from patients with RA
(n = 12, 7 female, age 29 to 72 years old, mean 51 years)
and patients with OA (n = 12, 6 female, age 39 to 77 years
old, mean 62 years). All of the patients fulfilled the Ameri-
can College of Rheumatology (ACR) diagnosis criteria for
RA and OA [14]. The RA patients had disease duration of
3–9 years and were classified as having erosive RA (Larsen
class IV–V). These patients presented high levels of
C-reactive protein (CRP) (32–298 mg/L, mean 73 mg/L),
anti-cyclic citrullinated peptide (anti-CCP) (28–458 U/ml,
mean 279.6 U/ml) and rheumatoid factor (RF) (38–
316 U/ml, mean 183.2 U/ml). Before arthroplasty, the
disease activity of each RA patient was evaluated using
the 28-joint disease activity score based on CRP
(DAS28-CRP) [15]. The degree of OA was graded by ex-
perienced orthopedic surgeons prior to surgery by x-ray
classification, and the patients’ Kellgren and Lawrence
grades ranged from 2–4. All of the patients provided
written informed consent to participate in this study. The
Ethics Committee of Shandong Provincial Qianfoshan
Hospital approved this study. RASFs were isolated from
synovial biopsy specimens of patients with RA as pre-
viously described [16] and cells between passages 4 and 7
were used for further study.
Stimulation assays
RASFs were plated in 12- and 24-well plates (5 × 104
and 3–5 × 105 cells/well) in Dulbecco’s modified Eagle’s
medium, and stimulated for the indicated time points
with the following agents: lipopolysaccharide (LPS fromEscherichia coli J5; SIGMA, St Louis, MO, USA), re-
combinant purified Sema4A (H00064218-P01, human,
Abnova, Taiwan). The dilution buffer, PBS, was applied
as the control to LPS or recombinant human sema-
phorin 4A (rhSema4A). Activation of signaling pathways
was blocked using BAY 11–7082, an NF-κB inhibitor,
WP1066, a Stat3 inhibitor, SU11274, a Met inhibitor or
PD98059, a mitogen-activated protein kinase (MAPK)
inhibitor (all from Calbiochem/EMD Millipore, Billerica,
MA, USA).Small interfering RNA transfection in RASFs
RASFs (2 × 105 cells in 100-mm-diameter dishes or
8.5 × 104 cells in 6-well plates) were transiently transfec-
ted with Sema4A small interfering RNA (siRNA, 50 nM,
SI00133560, SI04174107, QIAGEN, Hilden, Germany)
or negative control (QIAGEN, SI03650318) by Hiperfect
transfection reagent (QIAGEN) following the manufac-
turer’s instructions, and all experiments were performed
24–48 h after transfection. The specific siRNAs targeting
p50/p65, Plexin B1, Plexin D1 and Tim-2 were designed
and synthesized by GenePharma (Shanghai, China), and
the most effective single siRNA was used for further
experiments as follows: p65, sense strand: 5’-CCUC
CUUUCAGGAGAUGAAUU-3’ and anti-sense strand:
5’-UUCAU CUCCUGAAAGGAGGUU-3’; p50, sense
strand: 5’-GGCCUGAACAAAUGUUU CAUU-3’ and anti-
sense strand: 5’-UGAAACAUUUGUUCAGGCCUU-3’;
Plexin B1, sense strand: 5’-GGUUCUGGAUCAAUAUA
AU-3’ and anti-sense strand: 5’-AUUAUAUUGAUCCA
GAACC-3’; Plexin D1, sense strand: 5’- GGCCUCAAC
UUGAUCUUCU-3’ and anti-sense strand: 5’- AGAAGAU
CAAGUUGAGGCC-3’; Tim-2, sense strand: 5’- GCUGGG
UUCAAGACUGUUA-3’ and anti-sense strand: 5’- UAA
CAGUCUUGAACCCAGC-3’. Non-specific negative con-
trol siRNAs were also designed and synthesized (sense
strand: 5’-UUCUCCGAACGUGUCACG-3’ and anti-
sense strand: 5’-ACGUGACACGUUCGGAGAATT-3’).
The mock group was defined as that supplemented
with the transfection reagent only.Cell invasion assay
The cell invasion assay was performed in transwell ap-
paratus (Corning, Tewksbury, MA, USA). RASFs at a
density of 3 × 104 cells/well were grown to confluence
and incubated with 100 nM of siRNA or rhSema4A in
the upper compartment of the transwell apparatus for
48 h. After starvation, the lower compartment was filled
with DMEM with 10 % FBS and the plates were conti-
nually incubated at 37 °C for 24 h. The upper surface of
the insert was wiped with cotton swabs to remove non-
invading cells, and the bottom surface of the insert was
stained with Giemsa (Sigma, St Louis, MO, USA). The
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quantified in five random fields at × 100 magnification.
ELISA
After various treatments, serum-free conditioned media
samples were collected and centrifuged at 10,000 × g for
5 minutes to remove particulates. The supernatant was
harvested and assayed for IL-1β, TNF-α, and IL-6 (R&D
Systems, Minneapolis, MN, USA) by ELISA according to
the manufacturer’s instructions. Sema4A within synovial
fluid and culture media were determined as follows:
sandwich ELISA was developed utilizing goat anti-
Sema4A (C-46258, Santa Cruz, CA, USA) as capture anti-
body, rabbit anti-Sema4A (ab70178, Abcam, Cambridge,
UK) as detection antibody and horseradish peroxidase-
labeled goat anti-rabbit IgG antibody (Jackson, West Grove,
PA, USA) together with 3,3′,5,5′-tetramethylbenzidin for
color development. rhSema4A was tested at concen-
trations ranging from 1 to 1,000 ng/ml to generate a
standard curve.
Western blot analysis
Whole cell lysates were fractionated by 10 % SDS-
PAGE, transferred to polyvinylidene difluoride (PVDF)
membrane (Amersham Biosciences, Little Chalfont,
UK) and probed with antibody to phospho-Stat3, Stat3;
phospho-extracellular signal-regulated kinase (phosphor-
ERK), ERK; phospho-MET, MET; phospho-NF-κB, NF-κB
(Cell Signaling, Danvers, MA, USA), Sema4A (Abcam)
or glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(Santa Cruz). Bound antibodies were revealed with horse-
radish peroxidase-conjugated secondary antibodies (Santa
Cruz) and the blot developed using an ECL Plus detection
system (Thermo Scientific, Pittsburgh, PA, USA).
RNA extraction and quantitative (qRT-PCR)
RNA extraction and qRT-PCR was performed as previ-
ously described [17]. The details of the primers are as
followings: Sema4A: 5’-TAAAGTGAATGAAACCATTT
GT-3’ (forward), 5’-GTCTGTGAAATGTTTTACAGTGT-3’
(reverse); GAPDH: 5’-C ACCATCTTCCAGGAGC-3’
(forward); 5’-AGTGGACTCCACGACGTA-3’ (reverse).
GAPDH was used as internal loading control. Relative
mRNA levels were measured using the 2-Δ cycle thresh-
old (2-ΔCT) method. Three independent experiments
were completed and each reaction was performed in
triplicate.
Chromatin immunoprecipitation assay (ChIP)
RASFs were untreated or treated with LPS for 24 h
before the cells were fixed with 1 % formaldehyde in
medium for 10 minutes at room temperature. The sonic-
ation conditions were optimized to determine generation
of DNA fragments between 300 and 600 bp in length.Briefly, nuclear lysates were sheared with five to eight
pulses using an Ultrasonic Processor (80 W) with tubes
immersed in iced water. Each pulse cycle comprised 5 s
sonication followed by 25 s cooling down. Chromatin
was immunoprecipitated with IgG (Sigma) and anti-p65
(ab7970, Abcam). The association of p50 and p65 was
measured by RT-PCR on immunoprecipitated chromatin
by use of the following primers: 5’-TATACTGGCTGT
GACA-3’ (forward) and 5’-TGACAGATCCTGGCTT-3’
(reverse).
Statistical analyses
Statistical analysis of the data was performed using SPSS
V.16 software (SPSS, Armonk, NY, USA). The t test was
used to assess statistical differences between two groups.
The correlation between Sema4A level and TNF-α, and IL-6
in serum from RA patients was calculated by Spearman’s
correlation. P values <0.05 were considered significant.
The data are presented as standard deviation.
Results
Expression of Sema4A in the synovial tissue and serum of
patients with RA and its correlation with DAS28-CRP
To study the association between Sema4A and chronic
joint inflammation in RA, we first compared the expres-
sion profile of Sema4A mRNA in the synovial tissue of
patients with RA and those with non-inflammatory OA.
On qRT-PCR analysis there was a 5.56-fold higher level
of Sema4A in synovial tissues of patients with RA than
those with OA (Fig. 1a). Similarly, on western blot analysis
the Sema4A protein level was also higher in the synovial
tissues of patients with RA than those with OA (Fig. 1b).
We next performed ELISA to determine the secreted level
in a small cohort of patients with RA (n = 12) and OA
(n = 12). A significantly increased level of Sema4A was de-
tected in fluid from RA patients (514.3 ± 121.5 ng/mL)
compared to that from OA patients (174.9 ± 105.8 ng/mL)
(Fig. 1c). Then, we examined the correlation between
secreted Sema4A and DAS28-CRP, the disease activity
score for RA. Importantly, there was positive correlation
between soluble Sema4A and DAS28-CRP (r2 = 0.504,
P = 0.015; Fig. 1d). This suggests that the increased
Sema4A expression might be involved in the disease ac-
tivity of RA.
Investigating the effect of Sema4A on the invasion
of RASFs
The effect of Sema4A on the biological activity of human
RASFs was examined. RASFs were treated with various
concentrations of rhSema4A in serum-containing medium
for 24 h and the invasive viability was determined using
the transwell chamber. As shown in Fig. 2a, the in vitro in-
vasive ability increased when RASFs in the upper com-













































































Fig. 1 Increased expression of semaphorin 4A (Sema4A) in rheumatoid arthritis (RA). a Sema4A mRNA (relative to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH)) was detected by qRT-PCR and its expression increased in the synovial tissues in RA (n = 12) compared with those in
osteoarthrits (OA) (n = 12). b Western blot analysis showed that Sema4A protein increased in the synovial tissues of RA (n = 12) compared with
those of OA (n = 12) (ratio Sema4A/GAPDH RA 2.39 ± 0.15; OA 0.42 ± 0.12, P = 0.016 < 0.05). c The level of Sema4A was detected by ELISA in fluid
from RA and OA patients. d Correlation between soluble Sema4A in fluid from RA patients (n = 12) and disease activity score in 28 joints (DAS28).
*P <0.05 and **P <0.01 (statistically significant differences)
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(100 nM) with siRNA showed that the invasion was
blocked in comparison with the control groups (Fig. 2b).
Matrix metalloproteinases (MMPs) degrade the extracellu-
lar matrix, promoting cell invasion and their upregulation
has also been linked to the pathological process of RA [18].
To further support the pro-invasion ability of Sema4A, we
then examined the effect of Sema4A on MMP expression.
As shown in Fig. 2c, rhSema4A treatment induced MMP-3
and MMP-9 expression, which are important for cell inva-
sion [18]. In addition, RASFs, undergoing myofibroblast or
epithelial-mesenchymal transition (EMT)-like transition,
would be more likely to invade [19, 20]. Accordingly, our
data showed that rhSema4A treatment could also promote
the above transition as demonstrated by the induction of
the myofibroblast maker, α-smooth muscle actin (SMA)
and the EMT marker, vimentin (Fig. 2d) [19, 20].
Examining Sema4A expression following stimulation with LPS
To analyze the influence of Sema4A in immune response,
RASFs were treated with the toll-like receptor (TLR) ligand
[21] LPS for 24 h. On qRT-PCR there was a modest induc-
tion of Sema4A mRNA expression after stimulation ofRASFs with LPS at different concentrations (Fig. 3a). Time-
course analysis showed that Sema4A expression increased
after 3 h upon stimulation with LPS (1 μg/mL, Fig. 3b).
Western blot analysis of LPS-stimulated RASFs (1 μg/mL)
confirmed the induction of Sema4A protein after 12 h
(Fig. 3c). Further, the secreted level of Sema4A in the super-
natant of RASFs increased steadily after LPS stimulation
(Fig. 3d). These findings prompted us to study the function
of Sema4A during inflammation in detail.
Regulation of Sema4A expression by NF-κB signaling
Using the position-weight matrices available in GeneCards
(Genomics for SEMA4A Gene, Regulatory Elements for
SEMA4A Gene) [22], an NF-κB binding site on the
Sema4A promoter was identified (Fig. 4a). To further clar-
ify the role of the NF-κB subunits p50 and p65 in the
regulation of Sema4A [23], we used siRNA knockdown (both
100 nM) to silence p50 and p65 in RASFs. siRNA constructs
effective at silencing p50 or p65 (Fig. 4b), individually and in
combination, also inhibited Sema4A expression (Fig. 4b).
We also confirmed the above results in THP-1 cells with
p50 and p65 knocked down individually and in combin-
ation, resulting in suppressed Sema4A expression (Fig. 4b).
Fig. 2 Semaphorin 4A (Sema4A) regulates the invasive phenotype of synovial fibroblasts of rheumatoid arthritis (RASFs). The invasive ability of
RASFs as investigated by transwell apparatus after recombinant human semaphorin 4A (rhSema4A) (a) or silencing Sema4A (b) treatment, which
were depicted in × 100 magnification. Western blot was applied to detect the expression of matrix metalloproteinase (MMP)3 and MMP9 (c), as
well as alpha smooth actin (α-SMA) and vimentin (d) in RASFs after rhSema4A treatment at different concentrations. GAPDH glyceraldehyde-3-phosphate
dehydrogenase
Fig. 3 Effects of lipopolysaccharide (LPS) on the expression and secretion of semaphorin 4A (Sema4A). qRT-PCR was applied to detect the expression of
Sema4A after stimulation by LPS at various concentrations (a) or periods (b) in synovial fibroblasts of rheumatoid arthritis RASFs, respectively. c Sema4A
protein was assayed by western blot after LPS treatment in RASFs at indicated time points. d Secretion of Sema4A in the supernatant of RASFs was
detected by ELISA after LPS stimulation. *P <0.05 and **P <0.01 (statistically significant differences) GAPDH glyceraldehyde-3-phosphate dehydrogenase
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Fig. 4 Regulation of semaphorin 4A (Sema4A) expression by NF-κB. a Schematic illustration as the binding of NF-κB to the promoter of Sema4A.
b Synovial fibroblasts of rheumatoid arthritis (RASFs) and THP-1 cells were transfected with 50 nM of control, p50 or p65-siRNA, or p50 and p65
combined and incubated for the indicated time. Total extracts were separated by SDS-PAGE and western blot analysis was conducted for measurement
of Sema4A protein levels. c Chromatin immunoprecipitation (ChIP) analysis showed that p65 was recruited to the Sema4A promoter after treatment
with lipopolysaccharide (LPS) for 90 minutes. On ChIP analysis with control primers against distinct promoter regions there was no recruitment of p65.
Input, chromatin input before immunoprecipitation; Anti-p65, immunoprecipitated chromatin with anti-p65 antibody; IgG, immunoprecipitated
chromatin with control IgG. Effect of NF-κB inhibitor treatment on the LPS-induced Sema4A was detected by qRT-PCR (d) and western blot (e)
Wang et al. Arthritis Research & Therapy  (2015) 17:227 Page 6 of 11As NF-κB could regulate Sema4A expression at the tran-
scriptional level, we next investigated whether NF-κB could
directly bind to its promoter region. The results of ChIP
analysis showed that more p65 was bound to the Sema4A
promoter after treatment (Fig. 4c). Importantly, blocking
NF-κB signaling attenuated the LPS-induced expression of
Sema4A at the transcriptional (Fig. 4d) and translational
(Fig. 4e) levels, which demonstrates that the increased re-
cruitment of NF-κB to the Sema4A promoter after LPS
stimulation is indeed responsible for its induction in
RASFs.Production of IL-6 by Sema4A in RASFs
The production of the proinflammatory cytokine IL-6 was
analyzed in rhSema4A-stimulated RASFs with or without
LPS stimulation (1 μg/ml). Interestingly, rhSema4A treat-
ment induced the expression (Fig. 5a) and secretion of
IL-6 (Fig. 5b) in a dose-dependent manner. Notably, rhSe-
ma4A and LPS showed a duplicate effect on the induction
of IL-6 in RASFs (Fig. 5b). Accordingly, when RASFs were
transfected with control or Sema4A-specific siRNA for
48 h, there was significant reduction of both basal andLPS-stimulated expression of IL-6 after knocking down
Sema4A (50 nM, Fig. 5c). The basal IL-6 production was
reduced by 75 ± 7.2 % (P <0.05), whereas LPS-induced
IL-6 levels were reduced by 34.7 ± 3.8 % (P <0.05)
(Fig. 5c).Mediation of NF-κB during Sema4A functions
In further examining the pathological involvement of
Sema4A, our qRT-PCR analysis showed that silencing of
Plexin B1 attenuated the induction of IL-6 after rhSema4A
treatment more significantly than silencing of other re-
ceptors (Fig. 5d). Next, we wondered whether Sema4A in-
duced phosphorylation of signaling molecules in RASFs.
On immunoblot rhSema4A treatment upregulated the
phosphorylation levels of STAT3, MAPK, MET, and
NF-κB in a dose-dependent manner (Fig. 5e). We next ex-
amined the effects of various inhibitors targeting major
signaling pathways on Sema4A-induced IL-6 upregulation
in RASFs. As a result, rhSema4A-induced (50 ng/ml) IL-6
production was significantly inhibited by addition of BAY
11–7082 (10 uM), an NF-κB inhibitor, but not by
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Fig. 5 Semaphorin 4A (Sema4A) promotes IL-6 production in an NF-κB dependent way. a Synovial fibroblasts of rheumatoid arthritis (RASFs) were
treated with recombinant human semaphorin 4A (rhSema4A) at different concentrations and the expression of IL-6 was assayed by qRT-PCR. b Effects
of rhSema4A, with or without lipopolysaccharide (LPS) (1 μg/ml) stimulation, on the secretion of IL-6 in the supernatant of RASFs was detected by
ELISA. c After silencing Sema4A expression in RASFs, the IL-6 secretion was also detected by ELISA. d The expression of IL-6 in RASFs was detected by
qRT-PCR after silencing Plexin B1, Plexin D1 or Tim-2, respectively. e The phosphorlation of Stat3, mitogen-activated protein kinase (MAPK), Met and
NF-κB signaling in RASFs was analyzed by western blotting after treatment with rhSema4A (10 ng/ml) for the indicated periods. f IL-6 secretion in the
supernatant of RASFs was determined by ELISA after various treatments. *P <0.05 and **P <0.01 (statistically significant differences)
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not shown). These findings suggest that Sema4A induces
IL-6 production in RASFs via the NF-κB pathway.
Effect of Sema4A on the induction of TNF-α and IL-1β by
LPS-activated THP-1 cells
As RASFs do not secrete either TNF-α or IL-1β [24], we
next determined whether Sema4A overexpression could
affect the production of these cytokines by macrophages,
which also play an important role in RA. We thus
treated the macrophage cell line THP-1 with LPS and
performed qRT-PCR analysis of Sema4A. In these cells
Sema4A expression was also strongly upregulated in a
dose-dependent manner upon LPS treatment (Fig. 6a).
We confirmed that as in RASFs, LPS treatment also in-
duced Sema4A secretion in THP-1 cells (Fig. 6b). We
next tested whether Sema4A affected release of TNF-α
and IL-1β. rhSema4A treatment for 48 h induced TNF-α
and IL-1β more so than cells treated with PBS vehicle
alone (Fig. 6c, d). Next, we measured TNF-α and IL-1β
production by THP-1 cells treated with Sema4A for 48 h
and then activated with LPS (1 μg/ml) for 24 h. Com-
pared with the control and consistent with the obser-
vations made in RASFs, we observed that Sema4A
significantly promoted the release of these cytokines in
response to LPS, compared with the control without
LPS stimulation (Fig. 6c, d).Fig. 6 Semaphorin 4A (Sema4A) promotes TNF-α and IL-1β production in l
(b) of Sema4A were analyzed by qRT-PCR and ELISA in THP-1 after LPS stim
after recombinant human semaphorin 4A (rhSema4A), or in combination wCorrelation of the serum levels of Sema4A with TNF-α
and IL-6 in RA patients
Serum TNF-α and IL-6 levels were measured to better de-
termine the roles of Sema4A in RA. Significant correlation
was found between Sema4A and IL-6 levels (r2 = 0.723,
P = 0.008, Fig. 7a) and between Sema4A and TNF-α levels
(r2 = 0.711, P = 0.01, Fig. 7b). Sema4A levels were not sig-
nificantly correlated with IL-1β (data not shown). These
results further support the pro-inflammatory role of
Sema4A in RA.
Discussion
Previous studies showed that semaphorins such as
Sema3A, Sema3C, and Sema5A are involved in the
pathogenesis of RA [5–7]. Our results here demon-
strated first that the expression levels of Sema4A are sig-
nificantly higher in the synovial tissue and serum of
patients with RA compared to OA; this finding is con-
sistent with that of other semaphorins such as Sema5A.
Second, we demonstrated that Sema4A is involved in
the inflammatory response in RA. Bacterial and viral in-
fections are associated with the occurrence and patho-
genesis of flare reactions in RA [25] and the critical
involvement of TLR activation by its ligand, LPS, in the
initiation and persistence of inflammation in RA is well
recognized [26]. Here, the induction of Sema4A expres-
sion by LPS, together with the expression of Sema4A inipopolysaccharide (LPS)-activated THP-1. Expression (a) and secretion
ulation. Secretion of TNF-α (c) and IL-1β (d) was determined by ELISA
ith LPS treatment. *P <0.05 (statistically significant differences)
A B
C
Fig. 7 Correlation between serum semaphorin 4A (Sema4A) and cytokine levels in patients with rheumatoid arthritis. ELISA was performed to quantify
the serum levels of Sema4A, IL-6, and TNF-α in RA patients. Correlation between serum Sema4A and the level of IL-6 (a), and TNF-α (b) assessed by
Pearson correlation analysis. c A putative model illustrating the interactions of Sema4A/NF-κB in modulating cell phenotype through control of
IL-6 production
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persistent synovial inflammation in RA. Further, Sema4A
secretion levels also correlate with disease activity, further
supporting its role in the progression of RA.
In high-inflammation synovial tissues, RASFs can
undergo a process resembling EMT, a phenomenon found
in early developmental processes, tissue repair, fibrosis,
and carcinogenesis [19]. Additionally, RASFs exhibit a
gene expression profile characteristic of myofibroblasts(e.g., α-SMA and vimentin) [20]. In contrast to other
semaphorin studies focusing on immune cells such as T
and B cells, our study evaluated the regulation of Sema4A
on the biological activity of RASFs. Interestingly, our data
showed that Sema4A can induce EMT by upregulating
α-SMA and Vimentin expression in RASFs. Additionally,
Sema4A promotes the production of MMPs (MMP3 and
MMP9), which degrade the extracellular matrix (ECM)
[18], thereby providing space for RASFs to invade. These
Wang et al. Arthritis Research & Therapy  (2015) 17:227 Page 10 of 11findings suggest that Sema4A is a key effector disturbing
the joint microenvironment and a driving force that
directs proliferative synovium to destroy cartilage and
bone in RA.
Previous studies showed that Sema4A-mediated func-
tions are mediated via receptors such as TIM-2, Plexin
B1, and Plexin D1 [10, 11]. Our study demonstrated that
the induction of IL-6 by rhSema4A was significantly
inhibited by silencing Plexin B1, and partially inhibited
by silencing Plexin D1 and TIM-2. Therefore, during the
exacerbation of RA, although the expression of Sema3C
and Sema5A, together with Sema4A, increases in the syn-
ovial tissues and serum of patients with RA, these proteins
may function in a cell-specific or condition-specific man-
ner that offsets their likely functional redundancy.
IL-6, IL-1β, and TNF-α are all important cytokines
that stimulate RASFs and inflammatory cells to aggra-
vate synovial inflammation, resulting in joint destruction
[27, 28]. Our study also confirmed that Sema4A can ex-
acerbate the pathological progression by regulating the
production of these cytokines in a synergistic way with
LPS. Importantly, a significantly positive correlation was
identified between Sema4A expression and the produc-
tion of TNF-α and IL-6 in the serum of RA patients.
These data show multiple levels of interactions between
Sema4A and cytokines in vitro that occurs during in-
flammation in the presence of TLR ligands, and suggests
this as a potential treatment target for RA. It has been
reported that Sema4A can maintain the Treg cell sta-
bility in tumors [13]. The microenvironment of RA,
however, is different to that of tumors, and the balance
of Treg cells is dependent on the localized cytokine mi-
lieu [13]. Thus, the therapeutic effects of inhibiting
Sema4A merits further study, which also may increase
our understanding of the role of Tregs in RA.
To further determine the possible mechanism of ac-
tion of Sema4A, we explored intracellular signal trans-
duction pathways. Previous studies demonstrated that
NF-kB could be activated through Plexin B1 in endothe-
lial cells [29]. Here, the effect of Sema4A was linked to
the intracellular activation of NF-κB, MAPK, and STAT3
pathways, all of which represent major signaling cas-
cades involved in the activation of RASFs [30–32]. In
particular, production of IL-6 is NF-κB dependent,
which is essential for cytokine network triggering and
amplifying that escort for the chronic inflammatory re-
sponses of RA, largely through regulating the expression
of pro-inflammatory mediators such as TNF-α, IL-1β,
and IL-6 [27, 28]. Interestingly, our data showed that
Sema4A is a direct target of NF-κB, and blocking NF-κB
signaling attenuates LPS-induced Sema4A expression
and induction of IL-6 after rhSema4A treatment. Al-
though the suppression of p50 or p65 did not completely
eliminate the expression of Seme4A because of thesilencing efficiency or some other regulatory factors to-
wards Sema4A, these findings indicate that NF-κB is re-
quired for inflammation in RA, as mediated by Sema4A.
Interestingly, rhSema4A treatment also induced Sema4A
expression in RASFs (Additional file 1: Figure S1), which
may be due to an additional effect caused by the activa-
tion of NF-κB signaling. Collectively, these Sema4A-
mediated effects support the presence of a positive loop
between components of innate immunity, such as sti-
muli, cytokines, monocytes/macrophages, and cells from
the synovial stroma, such as RASFs, which may be
critical to the exacerbation of inflammation in RA.
Conclusion
In summary, we report the overexpression of Sema4A in
RA synovial tissue and fluid. In Fig. 7c, we propose a
model to illustrate how Sema4A/NF-κB promotes in-
flammation in RA through modulation of IL-6. Sema4A
activates NF-κB signaling through PlexinB1, which in
turn binds to the promoter of IL-6 and facilitates its
transcription. Notably, this effect can be strengthened by
LPS treatment.
Interestingly, Sema4A can also induce its own expres-
sion in an NF-κB-dependent manner. Although in vivo
experiments are needed, Sema4A inhibition seems to
have a dual therapeutic benefit, acting on two aspects of
RA pathogenesis (synovial invasion and inflammatory
response), reinforcing the potential utility of Sema4A in-
hibitors in RA.
Additional file
Additional file 1: Figure S1. Recombinant human semaphorin 4A
(rhSema4A) treatment induced its own expression in synovial fibroblasts
of rheumatoid arthritis (RASFs). (JPEG 759 kb)
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